Humira
Celltrion launches Humira biosimilar in US
July 7, 2023Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion
South Korean biopharmaceutical company Celltrion has announced that its US branch – Celltrion USA – has launched a Humira (adalimumab) …
Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis
November 4, 2020Research and Development Humira, biosimilar, celltrion, rheumatoid arthritis
Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free biosimilar CT-P17 proved comparable to …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023
November 18, 2019Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma
Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb), its biosimilar version of AbbVie’s Humira, the world’s best-selling drug, …
International revenue for world’s best-selling drug Humira falls 33.5% in the face of biosimilar competition
November 4, 2019Sales and Marketing AbbVie, Humira, pharma
With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – …
Despite some advantages, Novartis’ Cosentyx fails to outclass Humira in active psoriatic arthritis
November 1, 2019Medical Communications, Research and Development Cosentyx, Humira, Novartis, active psoriatic arthritis, pharma
Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …
Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis
September 27, 2019Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis
Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …
Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US
July 24, 2019Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma
It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …
FDA approves Pfizer’s Herceptin biosimilar Trazimera
March 12, 2019Manufacturing and Production, Sales and Marketing Humira, Pfizer, Trazimera, biosimilar, pharma
Patients in the US will now be able to access another biosimilar version of Herceptin (trastuzumab) with the FDA approval …
Eli Lilly’s Taltz shows superiority over AbbVie’s Humira
December 18, 2018Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system
A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …
NHS to save £300 million by switching to Humira biosimilars
November 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
Samsung and Bioepis launch third Humira biosimilar in Europe
October 17, 2018Research and Development, Sales and Marketing Amgen, Biogen, Humira, Imraldi, Samusng Bioepis, pharma
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of …
Amgen launches first biosimilar of best-selling Humira in Europe
October 16, 2018Manufacturing and Production, Sales and Marketing Amgen, Amgevita, Humira, biosimilar, pharma
Amgen has announced the launch of a proprietary biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) across all European markets, …
EU approval for Mylan and Fujifilm’s Humira biosimilar
September 21, 2018Medical Communications, Sales and Marketing EU, Europe, Humira, Mylan, biosimilar, pharma
The European Commission has approved its fifth biosimilar of the world’s best-selling drug, Abbvie’s Humira (adalimumab), granting marketing authorisation to …
Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis
September 13, 2018Research and Development Humira, Janssen, Tremfya, pharma, psoriasis
Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
